Dijous 11 de juny, el Dipòsit Digital no estarà operatiu de 15:00 a 17:00 h per tasques de manteniment. Disculpeu les molèsties.
El jueves 11 de Junio, el Dipòsit Digital no estará operativo de 15:00 a 17:00 h debido a tareas de mantenimiento. Disculpen las molestias.
Thursday, Jun 11th, the Digital Repository will be unavailable due to a system update.

Document type

Article

Version

Published version

Publication date

All rights reserved

Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/149576

Therapeutic targeting of HER2-CB2R heteromers in HER2-positive breast cancer

Journal Title

Director/Tutor

Journal ISSN

Volume Title

Abstract

There is a subtype of breast cancer characterized by the overexpression of the oncogene HER2. Although most patients with this diagnosis benefit from HER2-targeted treatments, some do not respond to these therapies and others develop resistance with time. New tools are therefore warranted for the treatment of this patient population, and for early identification of those individuals at a higher risk of developing innate or acquired resistance to current treatments. Here, we show that HER2 forms heteromer complexes with the cannabinoid receptor CB2R, the expression of these structures correlates with poor patient prognosis, and their disruption promotes antitumor responses. Collectively, our results support HER2-CB2R heteromers as new therapeutic targets and prognostic tools in HER2+ breast cancer

Subject (English)

Citation

Citation

BLASCO-BENITO, Sandra, et al. Therapeutic targeting of HER2-CB2R heteromers in HER2-positive breast cancer. Proceedings of the National Academy of Sciences of the United States of America - PNAS. 2019. Vol. 116, num. 9, pags. 3863-3872. ISSN 0027-8424. [consulted: 12 of June of 2026]. Available at: https://hdl.handle.net/2445/149576

Export metadata

JSON - METS

Share record